NVO - European Drug Regulator To Consider Expanded Use Of Novo Nordisk's Wegovy Weight-Loss Drug | Benzinga
The European Medicines Agency (EMA) is set to discuss extending the application of Novo Nordisk A/S’s (NYSE:NVO) weight loss drug, Wegovy (semaglutide), to include the reduction of stroke and heart attack risks.
This move, stemming from the SELECT trial, is anticipated to enhance the Danish pharmaceutical company’s argument for integrating Wegovy into public health systems across Europe.
The EMA’s drug assessment panel will scrutinize the potential new usage during its monthly meeting scheduled for 22-25 January 2024.
Also Read: Weightloss Drugs Ozempic And Wegovy’s ...